<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03602495</url>
  </required_header>
  <id_info>
    <org_study_id>ZGDD3</org_study_id>
    <nct_id>NCT03602495</nct_id>
  </id_info>
  <brief_title>Donafenib in 131I-Refractory Differentiated Thyroid Cancer</brief_title>
  <official_title>A Multicenter, Randomized, Double-Blind,Placebo-controlled,Phase 3 Trial of Donafenib in 131IRefractory Differentiated Thyroid Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Suzhou Zelgen Biopharmaceuticals Co.,Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Suzhou Zelgen Biopharmaceuticals Co.,Ltd</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Donafenib for advanced 131I-refractory/resistant differentiated thyroid cancer(DTC).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This phase 3 study of donafenib, an oral multikinase inhibitor that targets Raf kinase and
      receptor tyrosine kinases, is to assess efficacy and safety in patients with
      131I-refractory/resistant differentiated thyroid cancer.The study is a
      randomised,multicentre,double-blind,placebo-controlled,study.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 26, 2018</start_date>
  <completion_date type="Anticipated">March 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free Survival</measure>
    <time_frame>From randomization of the first subject until the last subject complete 24 months treatment</time_frame>
    <description>PFS was defined as the time from date of randomization to disease progression radiological or death due to any cause, whichever occurs first. Subjects without progression or death at the time of analysis were censored at their last date of tumor evaluation.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>From randomization of the first subject until the last subject complete 48 months treatment</time_frame>
    <description>OS is defined as the time from date of randomization to death due to any cause. Subjects still alive at the time of analysis were censored at their last date of last contact</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate(ORR)</measure>
    <time_frame>From randomization of the first subject until the last subject complete 24 months treatment</time_frame>
    <description>ORR is defined as the percentage of subjects with total number of Complete Response(CR)+total number of Partial Response(PR).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Control Rate(DCR)</measure>
    <time_frame>From randomization of the first subject until the last subject complete 24 months treatment</time_frame>
    <description>DCR is defined as the percentage of subjects whose best response was not Progressive Disease (PD) according to Response Evaluation Criteria in Solid Tumors (RECIST) (= total number of Complete Response (CR) + total number of Partial Response (PR) + total number of Stable Disease (SD); CR, PR, or SD had to be maintained for at least 28 days from the first demonstration of that rating)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time To Disease Progression (TTP)</measure>
    <time_frame>From randomization of the first subject until the last subject complete 24 months treatment</time_frame>
    <description>TTP was defined as the time from date of randomization to disease progression radiological. Subjects without progression at the time of analysis were censored at their last date of tumor evaluation.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">204</enrollment>
  <condition>Differentiated Thyroid Cancer</condition>
  <arm_group>
    <arm_group_label>Donafenib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Donafenib 300mg bid for each 28 days cycle.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo 300mg bid for each 28 days cycle.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Donafenib</intervention_name>
    <description>after continuing to intolerance or progress in double blind treatment period,for progress but tolerance into open therapy period for Donafenib evaluated by investigator</description>
    <arm_group_label>Donafenib</arm_group_label>
    <other_name>treatment drug</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>after continuing to intolerance or progress in double blind treatment period,for progress but tolerance into open therapy period for Donafenib evaluated by investigator</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Placebo for Donafenib</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Advanced or metastases thyroid cancer;

          -  Subjects must have histologically or cytologically confirmed diagnosis of one of the
             following differentiated thyroid cancer (DTC) subtypes: papillary thyroid cancer
             (PTC),follicular thyroid cancer (FTC) or Hurthle cell,poorly differentiated carcinoma
             ;

          -  Subjects must show evidence of disease progression within 14 months prior to signing
             informed consent, according to RECIST 1.1 assessed and confirmed by central
             radio-graphic review of CT scans.

          -  Measurable disease meeting the following criteria and confirmed by central
             radiographic review:

               1. At least 1 lesion of greater than or equal to 1.0 cm in the longest diameter for
                  a non-lymph node or greater than or equal to 1.5cm in the short-axis diameter for
                  a lymph node which is serially measurable according to RECIST 1.1 using
                  computerized tomography.

               2. Lesions that have had external beam radiotherapy (EBRT) or locoregional therapies
                  such as radio-frequency (RF) ablation must show evidence of progressive disease
                  based on RECIST 1.1 to be deemed a target lesion;

               3. Bone metastases lesion is non-measurable.

          -  Subjects must be 131I-refractory / resistant as defined by at least one of the
             following:

               1. One or more measurable lesions that do not demonstrate iodine uptake on any
                  radio-iodine scan

               2. One or more measurable lesions that has progressed by RECIST 1.1 within 14 months
                  of 131I therapy, despite demonstration of radio-iodine avidity at the time of
                  that treatment by pre-treatment scanning.

               3. Cumulative activity of 131I of &gt;600 mCi or 22 gigabequerels (GBq)

          -  Subjects may have not received molecular targeted therapy;

          -  Subjects with known brain metastases who have completed whole brain radiotherapy,
             stereotactic radiosurgery or complete surgical resection, will be eligible if they
             have remained clinically stable, asymptomatic and off of steroids for one month

          -  Subjects must tolerate to thyroxin ,and TSH suppression (TSH less than 0.5 mU/mL);

          -  Before 14 days prior to study entry,(before laboratory examination for 14days no blood
             transfusion,not use albumin and Hematopoietic Stimulating Factor),Adequate laboratory
             examination :

               1. Absolute neutrophil count (ANC) greater than or equal to 1500/ mm3;

               2. Platelets greater than or equal to 100,000/mm3 ;

               3. Hemoglobin greater than or equal to 9.0g/dL

               4. Adequate blood coagulation function:International Normalized Ratio(INR)≤2.

               5. Adequate liver function: Bilirubin less than or equal to 1.5 x the upper limit of
                  normal(ULN) ;Alkaline phosphatase, alanine aminotransferase (ALT), and aspartate
                  aminotransferase (AST) less than or equal to 2.5 x the upper limit of normal
                  (ULN),for liver metastasis ALT and AST less than or equal to 5.0 x the upper
                  limit of normal (ULN);

               6. serum creatinine less than or equal to 1.5 x the upper limit of normal
                  (ULN);creatinine clearance less than 50ml/min

          -  Subjects must have an Eastern Cooperative Oncology Group (ECOG) Performance Status of
             0~2；

          -  Life expectancy of at least 3 months;

          -  All females must have a negative serum or urine pregnancy test. Females of
             childbearing potential and male subjects who are partners of women of childbearing
             potential must use or their partners must use a highly effective method of
             contraception;

          -  Voluntary provision of written informed consent and the willingness and ability to
             comply with all aspects of the protocol.

          -  Swallow oral drugs and keep them in the body

        Exclusion Criteria:

          -  Other pathologic subtypes of the thyroid,undifferentiated carcinoma,medullary
             carcinoma,lymphoma and sarcoma etc;

          -  Prior treatment to TKI or other molecular targeted drugs；

          -  Subjects who have received any chemotherapy or extra radiotherapy（in addition to low
             dose chemotherapy for radiosensitization） within 30 days prior to the first dose of
             study drug and should have recovered from any toxicity related to previous anti-cancer
             treatment;

          -  Known or suspect to TKI food allergy;in the study be allergic to drugs;

          -  Active malignancy (except for differentiated thyroid carcinoma, or definitively
             treated melanoma in-situ, basal or squamous cell carcinoma of the skin, or carcinoma
             in-situ of the cervix) within the past 5 years;

          -  Major surgery, open biopsy or severe trauma within 4 weeks prior to the first dose of
             study drug;

          -  An unhealed wound, ulcer, or fracture;

          -  Evidence of bleeding and coagulation disorders;

          -  Using the antiplatelet drugs(except for a small dose of aspirin which is not more than
             100mg)；

          -  The risk of Infiltration and bleeding of the trachea, bronchi and esophagus，not using
             topical treatment berore randomize;

          -  Bleeding of more than Grade 3 within 3 months prior to the first dose of study drug;

          -  Significant cardiovascular impairment: history of congestive heart failure greater
             than New York Heart Association (NYHA) Class II, unstable angina; myocardial
             infarction or stroke within 6 months of the first dose of study drug;

          -  Cardiac arrhythmia requiring medical treatment,QTc more than 480ms；Adequately
             controlled blood pressure with or without antihypertensive medications, defined as BP
             less than 140/90 mmHg using at least 2 kinds of medicine;

          -  Venous or arterial thromboembolic events，cerebral blood-vessel accident，arterial
             thrombosis，pulmonary embolism，deep-venous thrombosis，within 6 months of the first dose
             of study drug;

          -  Active infection more than Grade 2 (any infection requiring treatment);

          -  All chemotherapy or radiation-related toxicities must have resolved to less than Grade
             2 severity, except alopecia neurotoxicity;

          -  HIV infectious,active infection of the HCV and HBV (HBV-DNA more than 1000
             copise/ml，expect the chronic asymptomatic HBV carrier);

          -  Epileptic seizure being drug treatment;

          -  Using the strong - acting CYP3A4
             inducer(phenytoin,carbamazepine,rifampicin,rifapentine,phenobarbital) within 7 days of
             the first dose of study drug;

          -  using biological reaction regulator(g-csf granulocyte colony stimulating factor)
             within 21 days of the first dose of study drug;

          -  The drug abuse,medicine,psychology and social disease which may be have an effect on
             study result;

          -  Any malabsorption disease;

          -  The disease which is unstable and harm to safty and research compliance of patient;

          -  Take the other clinical research treatment in the study and within 4 weeks of the
             first dose of study drug;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lin Yan Song, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Peking Union Medical College Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lin Yan Song, MD</last_name>
    <phone>13671116837</phone>
    <email>linys@pumch.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Peking Union Medical College Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lin Yan Song, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>July 18, 2018</study_first_submitted>
  <study_first_submitted_qc>July 18, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 26, 2018</study_first_posted>
  <last_update_submitted>October 21, 2019</last_update_submitted>
  <last_update_submitted_qc>October 21, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 22, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thyroid Neoplasms</mesh_term>
    <mesh_term>Thyroid Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

